A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

Recruiting

Phase 1

Laroprovstat & EzetimibeA Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

Sponsor:

AstraZeneca

Code:

NCT07622433

Conditions

Healthy Participants

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

Laroprovstat/ezetimibe FCDP

Laroprovstat STP

Ezetimibe STP

Laroprovstat/ezetimibe FCDP-slow variant

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-24. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-06-16.